Series B - Jaguar Gene Therapy

Series B - Jaguar Gene Therapy

Investment Firm

Overview

Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

Announced Date

Apr 13, 2021

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Deerfield

Deerfield

Deerfield is a debt and early_stage_venture firm.

Eli Lilly

Eli Lilly

No designation

Participant Investors

6

Investor Name
Participant InvestorSean P. Nolan
Participant InvestorEli Lilly
Participant InvestorDeerfield
Participant InvestorARCH Venture Partners
Participant InvestorGoldman Sachs

Round Details and Background

Jaguar Gene Therapy raised $139000000 on 2021-04-13 in Series B

Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Apr 13, 2021
Series B - Jaguar Gene Therapy
6-139.0M
Feb 25, 2021
Series A - Jaguar Gene Therapy
1-undefined
Mar 29, 2022
Venture Round - Jaguar Gene Therapy
2-undefined

Recent Activity

There is no recent news or activity for this profile.